Investor profile

Osage University Partners

As of November 2026, Osage University Partners is linked to 1 startup in the Triangle Startups directory. Its most recent recorded round is IMMvention Therapeutix's $6.9 million venture round in December 2020.

Venture firm that invests exclusively in startups commercializing university research, in partnership with university technology-transfer offices. Investor in IMMvention Therapeutix (Durham).

Venture fund

Bala Cynwyd, PA

Visit website

Directory portfolio

Companies connected here

Latest company funding first, including rounds involving other investors. Unknown dates last.

IMMvention Therapeutix
Latest company funding · Dec 23, 2022
Preclinical biotech developing oral small-molecule BACH1 inhibitors for sickle cell disease and other chronic conditions, with its systemic program licensed to Novo Nordisk.

Portfolio coverage reflects public company-investor links tracked in this directory and may not represent the investor's full portfolio.